Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MRE (medco research) -- Ignore unavailable to you. Want to Upgrade?

To: Harold V who wrote (95)	5/26/1998 12:09:00 PM
From: Harold V	Read Replies (1) \| Respond to of 192

I'm hoping that MRE's share price will respond positively this week to the conference MRE and a couple of other companies hosted in Europe at the end of last week. Adenosine products have great potential in the cardiovasular arena. If, for example, MRE can get an application approved for identifying far more precisely the damage heart attacks cause to the heart muscle and/or the use of Adenosine to ensure greater safety in angioplasty, its profits will increase far beyond MRE's present drugs for arythmias in the heart beat (Adenocard) and the use of Adenoscan a quick, less expensive, and less time-consuming way to diagnose patients' cardiovascular health (replacing tread mill exercises, etc. For the record, MRE has stated that its Adenosine products that have already been identified have a market potential of $3 BILLION! Harold V